» Articles » PMID: 17457052

Stem Cell Chromatin Patterns: an Instructive Mechanism for DNA Hypermethylation?

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2007 Apr 26
PMID 17457052
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Epigenetic gene silencing, and associated promoter CpG island DNA hypermethylation, is an alternative mechanism to mutations by which tumor suppressor genes may be inactivated within a cancer cell. These epigenetic changes are prevalent in all types of cancer, and their appearance may precede genetic changes in premalignant cells and foster the accumulation of additional genetic and epigenetic hits. These epigenetically modified genes constitute important categories of tumor suppressor genes including cell cycle regulators, pro-differentiation factors, and anti-apoptotic genes, and many of these genes are known to play a role in normal development. While the silencing of these genes may play an essential role in tumor initiation or progression, the mechanisms underlying the specific targeting of these genes for DNA hypermethylation remains to be determined. The large numbers of epigenetically silenced genes that may be present in any given tumor, and the clustering of silenced genes within single cell pathways, begs the question of whether gene silencing is a series of random events resulting in an enhanced survival of a premalignant clone, or whether silencing is the result of a directed, instructive program for silencing initiation reflective of the cells of origin for tumors. In this regard, the current review stresses the latter hypothesis and the important possibility that the program is linked, at least for silencing of some cancer genes, to the epigenetic control of stem/precursor cell gene expression patterns.

Citing Articles

DNA hypomethylation promotes UHRF1-and SUV39H1/H2-dependent crosstalk between H3K18ub and H3K9me3 to reinforce heterochromatin states.

Liu Y, Hrit J, Chomiak A, Stransky S, Hoffman J, Tiedemann R Mol Cell. 2024; 85(2):394-412.e12.

PMID: 39631394 PMC: 11741932. DOI: 10.1016/j.molcel.2024.11.009.


The role of aberrant DNA methylation in cancer initiation and clinical impacts.

Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher E, Scott C Ther Adv Med Oncol. 2024; 16:17588359231220511.

PMID: 38293277 PMC: 10826407. DOI: 10.1177/17588359231220511.


Potential methylation-regulated genes and pathways in hepatocellular neoplasm, not otherwise specified.

Zhou S, Li M, Ostrow D, Ruble D, Mascarenhas L, Pawel B Front Oncol. 2022; 12:952325.

PMID: 36212481 PMC: 9532972. DOI: 10.3389/fonc.2022.952325.


Differential Transcriptomes and Methylomes of Trophoblast Stem Cells From Naturally-Fertilized and Somatic Cell Nuclear-Transferred Embryos.

Sun J, Zheng W, Liu W, Kou X, Zhao Y, Liang Z Front Cell Dev Biol. 2021; 9:664178.

PMID: 33869230 PMC: 8047118. DOI: 10.3389/fcell.2021.664178.


EPISCORE: cell type deconvolution of bulk tissue DNA methylomes from single-cell RNA-Seq data.

Teschendorff A, Zhu T, Breeze C, Beck S Genome Biol. 2020; 21(1):221.

PMID: 32883324 PMC: 7650528. DOI: 10.1186/s13059-020-02126-9.


References
1.
Laverriere A, MacNeill C, Mueller C, Poelmann R, Burch J, Evans T . GATA-4/5/6, a subfamily of three transcription factors transcribed in developing heart and gut. J Biol Chem. 1994; 269(37):23177-84. View

2.
Lachner M, OSullivan R, Jenuwein T . An epigenetic road map for histone lysine methylation. J Cell Sci. 2003; 116(Pt 11):2117-24. DOI: 10.1242/jcs.00493. View

3.
Ohm J, McGarvey K, Yu X, Cheng L, Schuebel K, Cope L . A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet. 2007; 39(2):237-42. PMC: 2744394. DOI: 10.1038/ng1972. View

4.
Kinzler K, Vogelstein B . Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 1997; 386(6627):761, 763. DOI: 10.1038/386761a0. View

5.
Kirmizis A, Bartley S, Farnham P . Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther. 2003; 2(1):113-21. View